Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

Phase 1

Completed

Conditions: Metastatic Cancer
Breast Cancer

First Posted Date: 2006-03-13

Last Posted Date: 2015-04-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT00301730

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: Cetuximab
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Conventional Surgery
Radiation: Radiation Therapy

First Posted Date: 2006-03-10

Last Posted Date: 2013-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00301028

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: docetaxel
Biological: Trastuzumab
Drug: doxorubicin hydrochloride
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-02-24

Last Posted Date: 2024-01-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 121

Registration Number: NCT00295893

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Tarceva
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2006-02-22

Last Posted Date: 2012-08-09

Lead Sponsor: OSI Pharmaceuticals

Target Recruit Count: 143

Registration Number: NCT00294762

Locations: 🇺🇸
Alegent Healthcare, Omaha, Nebraska, United States
🇺🇸
Hematology-Oncology Associates, SJ, PA - Virtua Health, Mount Holly, New Jersey, United States
🇺🇸
Boston Baskin Cancer Groupd/b/a U. of Tennessee Cancer Inst., Memphis, Tennessee, United States

and more 40 locations

Phase II Study of ZD6474 in Advanced NSCLC

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: ZD6474
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-02-13

Last Posted Date: 2016-05-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00290537

Locations: 🇺🇸
University of Texas M.D.Anderson Cancer Center, Houston, Texas, United States

Maintenance Chemotherapy in Metastatic Breast Cancer

Phase 3

Conditions: Breast Cancer

First Posted Date: 2006-02-09

Last Posted Date: 2006-02-09

Lead Sponsor: MANTA 1 Study Italian Collaborative Group

Target Recruit Count: 524

Registration Number: NCT00289263

Locations: 🇮🇹
Azienda Ospedaliera Pisana, Pisa, PI, Italy
🇮🇹
Oncology Institute, Bari, Italy
🇮🇹
National Cancer Research Institute, Genoa, Italy

and more 4 locations

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: erlotinib hydrochloride

First Posted Date: 2006-02-07

Last Posted Date: 2018-12-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 86

Registration Number: NCT00287989

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size
Extraocular Extension Melanoma
Iris Melanoma
Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IV Melanoma